# PDUFA dates February 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-02

> 50 FDA catalysts are dated in February 2027, including 11 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in February 2027?

PDUFA dates in February 2027: AQVESME™ (mitapivat, AGIO) on February 1, 2027; Yeztugo® (lenacapavir, GILD) on February 2, 2027; TRUSELTIQ® (infigratinib, BBIO) on February 4, 2027; Verastem, Inc. (VSTM) on February 7, 2027; tinlarebant (BLTE) on February 12, 2027; ZORYVE (roflumilast, ARQT) on February 23, 2027; and 5 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2027-02)

Source: Press release filed with the SEC (EX-99), accession 0001439222-26-000129, https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/fda-calendar/2027-02#answer

## PDUFA dates in February 2027

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| February 1, 2027 | AGIOS PHARMACEUTICALS, INC. | AGIO | AQVESME™ (mitapivat) | sickle cell disease | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm) |
| February 2, 2027 | GILEAD SCIENCES, INC. | GILD | Yeztugo® (lenacapavir) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm) |
| February 4, 2027 | BridgeBio Pharma, Inc. | BBIO | TRUSELTIQ® (infigratinib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm) |
| February 7, 2027 | Verastem, Inc. | VSTM |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926123386/tm2628982d2_ex99-1.htm) |
| February 12, 2027 | BELITE BIO, INC | BLTE | tinlarebant |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm) |
| February 23, 2027 | Arcutis Biotherapeutics, Inc. | ARQT | ZORYVE (roflumilast) | infants with atopic dermatitis down | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm) |
| February 27, 2027 | Cullinan Therapeutics, Inc. | CGEM | zipalertinib |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526454408/cgem-ex99_1.htm) |
| February 28, 2027 | BIOMARIN PHARMACEUTICAL INC | BMRN | VOXZOGO (vosoritide) | achondroplasia | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm) |
| February 28, 2027 | Sarepta Therapeutics, Inc. | SRPT |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/873303/000119312526449721/srpt-20260930.htm) |
| February 28, 2027 | PALVELLA THERAPEUTICS, INC. | PVLA | rapamycin |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm) |
| February 28, 2027 | Apnimed, Inc. | APMD | Strattera (atomoxetine) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm) |

## All catalysts in February 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 1, 2027 | [AQVESME™ (mitapivat) PDUFA date](https://sec-api.dev/pdufa/mitapivat) | AGIO | sickle cell disease | scheduled | "•New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm)) |
| February 2027 | [LEE011 primary completion](https://sec-api.dev/pdufa/lee011) | NVS |  | scheduled | "NCT02934568 (Ribociclib (LEE011) Rollover Study for Continued Access): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02934568)) |
| February 2, 2027 | [Yeztugo® (lenacapavir) PDUFA date](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | scheduled | "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm)) |
| February 2027 | [KISQALI® (ribociclib) primary completion](https://sec-api.dev/pdufa/ribociclib) | NVS | Melanoma | scheduled | "NCT04417621 (Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04417621)) |
| February 4, 2027 | [TRUSELTIQ® (infigratinib) PDUFA date](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | scheduled | "- Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with Priority Review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| February 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Sjogrens Syndrome | scheduled | "NCT06741969 (Nipocalimab in Moderate to Severe Sjogren's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741969)) |
| February 2027 | [Cipargamin primary completion](https://sec-api.dev/pdufa/cipargamin) | NVS | Uncomplicated Plasmodium Falciparum Malaria | scheduled | "NCT07811908 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811908)) |
| February 2027 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT06946797 (A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06946797)) |
| February 2027 | [Zasocitinib (dose a) primary completion](https://sec-api.dev/pdufa/zasocitinib-dose-a) | TAK | Hidradenitis Suppurativa | scheduled | "NCT07244263 (A Study of Zasocitinib in Adults With Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07244263)) |
| February 7, 2027 | [Verastem, Inc. PDUFA date](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | scheduled | "FDA decision on NDA for AVMAPKI FAKZYNJA CO - PACK Blister Pack by February 7, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926123386/tm2628982d2_ex99-1.htm)) |
| February 2027 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07170917 (Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07170917)) |
| February 2027 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Atrial Fibrillation (AF) | scheduled | "NCT07175428 (Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07175428)) |
| February 2027 | [Guselkumab subcutaneous primary completion](https://sec-api.dev/pdufa/guselkumab-subcutaneous) | JNJ | Colitis, Ulcerative | scheduled | "NCT06260163 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260163)) |
| February 2027 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | scheduled | "NCT06271837 (A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06271837)) |
| February 2027 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | scheduled | "NCT06807424 (A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807424)) |
| February 2027 | [Teduglutide primary completion](https://sec-api.dev/pdufa/teduglutide) | TAK | Short Bowel Syndrome | scheduled | "NCT06973304 (A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973304)) |
| February 11, 2027 | [INTEGRATED BIOPHARMA INC interim data readout](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | scheduled | "After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending the period ending February 11, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1016504/000143774926003803/inbp20251231_10q.htm)) |
| February 2027 | [Bedaquiline (tmc207) primary completion](https://sec-api.dev/pdufa/bedaquiline-tmc207) | JNJ | Tuberculosis, Multidrug-Resistant | delayed | "NCT02354014 (Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB): Overall Status SUSPENDED; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02354014)) |
| February 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Graves' Disease | scheduled | "NCT06984627 (A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06984627)) |
| February 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Acute Coronary Syndrome | scheduled | "NCT07102628 (Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102628)) |
| February 2027 | [AZD4144 primary completion](https://sec-api.dev/pdufa/azd4144) | AZN | Sepsis; Acute Kidney Injury | scheduled | "NCT07215702 (A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215702)) |
| February 12, 2027 | [Tinlarebant PDUFA date](https://sec-api.dev/pdufa/tinlarebant) | BLTE |  | scheduled | "Fee Act (PDUFA) target action date of February 12, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm)) |
| February 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | scheduled | "NCT03407144 (Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03407144)) |
| February 2027 | [Sub-retinal administration of ocu400-301 primary completion](https://sec-api.dev/pdufa/sub-retinal-administration-of-ocu400-301) | OCGN | Retinitis Pigmentosa | scheduled | "NCT06388200 (A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388200)) |
| February 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Lymphoma, Mantle Cell | scheduled | "NCT02972840 (A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02972840)) |
| February 2027 | [MRNA-1403 primary completion](https://sec-api.dev/pdufa/mrna-1403) | MRNA | Acute Gastroenteritis; Norovirus Acute Gastroenteritis | scheduled | "NCT06592794 (A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06592794)) |
| February 2027 | [AUGTYRO (repotrectinib) primary completion](https://sec-api.dev/pdufa/repotrectinib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06140836 (A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06140836)) |
| February 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease | scheduled | "NCT06233461 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06233461)) |
| February 2027 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07424144 (An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07424144)) |
| February 2027 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Psoriatic Arthritis | scheduled | "NCT07486960 (Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07486960)) |
| February 2027 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Chronic Kidney Disease With High Proteinuria | scheduled | "NCT06087835 (Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06087835)) |
| February 2027 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Venous Thromboembolism (VTE) | scheduled | "NCT07015905 (REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-20 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015905)) |
| February 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT04529772 (A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04529772)) |
| February 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Cancer | scheduled | "NCT05629234 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629234)) |
| February 2027 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Dyslipidaemia | scheduled | "NCT06834932 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834932)) |
| February 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria (CSU) | scheduled | "NCT06868212 (A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868212)) |
| February 23, 2027 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | infants with atopic dermatitis down | scheduled | "•The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm)) |
| February 2027 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Nephritis | scheduled | "NCT05138133 (Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05138133)) |
| February 2027 | [Afinitor (everolimus) primary completion](https://sec-api.dev/pdufa/everolimus) | NVS | Tuberous Sclerosis Complex | scheduled | "NCT02962414 (Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02962414)) |
| February 2027 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT04133636 (A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04133636)) |
| February 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced HER2+Breast Cancer | scheduled | "NCT04208178 (Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04208178)) |
| February 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced Breast Cancer | scheduled | "NCT04524000 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04524000)) |
| February 2027 | [XPHOZAH® (tenapanor) primary completion](https://sec-api.dev/pdufa/tenapanor) | ARDX | Chronic Idiopathic Constipation (CIC) | scheduled | "NCT07382167 (A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07382167)) |
| February 27, 2027 | [Zipalertinib PDUFA date](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | scheduled | "An NDA for zipalertinib monotherapy for relapsed EGFR ex20ins NSCLC remains under review with a Prescription Drug User Fee Act target action date of February 27, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526454408/cgem-ex99_1.htm)) |
| February 28, 2027 | [VOXZOGO (vosoritide) PDUFA date](https://sec-api.dev/pdufa/vosoritide) | BMRN | achondroplasia | scheduled | "•In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000023/bmrn-20260930.htm)) |
| February 28, 2027 | [Sarepta Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | scheduled | "As of the date of this Quarterly Report, we anticipate a PDUFA target action date of February 28, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/873303/000119312526449721/srpt-20260930.htm)) |
| February 28, 2027 | [Rapamycin PDUFA date](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | scheduled | "FDA Accepts NDA for QTORIN Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm)) |
| February 28, 2027 | [Strattera (atomoxetine) PDUFA date](https://sec-api.dev/pdufa/atomoxetine) | APMD |  | scheduled | "U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi, and assigned a PDUFA target action date of February 28, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm)) |
| February 2027 | [Adi-peg 20 primary completion](https://sec-api.dev/pdufa/adi-peg-20) | PII | Glioblastoma Multiforme (GBM) | scheduled | "NCT04587830 (ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-28 (ESTIMATED); Lead Sponsor Polaris Group." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04587830)) |
| February 2027 | [Mevrometostat primary completion](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06551324 (A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-28 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06551324)) |

Other months: https://sec-api.dev/fda-calendar/2027-01 , https://sec-api.dev/fda-calendar/2027-03. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates February 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-02

```bibtex
@misc{secapidev_fda_calendar_2027_02_20261116,
  title        = {PDUFA dates February 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-02}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_02_20261116","title":"PDUFA dates February 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-02","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
